Naureen Alim, MD
Rheumatology · Houston, TXNPI 1134374184
Payments from drug & device makers
Across 863 payments — averaging $459.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$268K
- AstraZeneca$54K
- Amgen$31K
- Sanofi$28K
- GSK$10K
- US Oncology Corporate, Inc.$1K
- plus $4K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 417 | $268,183 |
| AstraZeneca(2 entities) | 87 | $53,736 |
| Amgen(2 entities) | 88 | $31,324 |
| Sanofi | 57 | $27,695 |
| GSK | 22 | $10,308 |
| US Oncology Corporate, Inc. | 4 | $1,123 |
| UCB, Inc. | 22 | $542 |
| Johnson & Johnson(2 entities) | 20 | $510 |
| Lilly USA, LLC | 16 | $420 |
| Aurinia Pharma U.S., Inc. | 12 | $366 |
| Pfizer | 23 | $338 |
| Mallinckrodt Hospital Products Inc. | 11 | $293 |
| Novartis | 13 | $251 |
| Arcutis Biotherapeutics, Inc. | 5 | $202 |
| E.r. Squibb & Sons, L.L.C. | 11 | $193 |
| Genentech USA, Inc. | 5 | $126 |
| Cardinal Health 110 LLC | 1 | $100 |
| Radius Health, Inc. | 5 | $99 |
| Boehringer Ingelheim | 4 | $95 |
| Organon | 6 | $95 |
| Merck | 5 | $90 |
| Mallinckrodt Enterprises LLC | 4 | $87 |
| Bristol Myers Squibb | 4 | $72 |
| CSL Behring | 3 | $57 |
| Sobi, Inc | 3 | $56 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Ultragenyx Pharmaceutical Inc. | 2 | $43 |
| Grifols USA, LLC | 2 | $37 |
| Sandoz | 1 | $32 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $30 |
| Gilead | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Octapharma USA, Inc. | 1 | $20 |
| Medexus Pharma, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
How this compares
$396,673 in reported general payments places this provider in the 85th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Houston
- Philip WallerHouston$4.9M
- Qaiser RehmanHouston$2.3M
- Michelle EisenbergHouston$1.8M
- Abigail NeimanHouston$1.7M
- Maureen MayesHouston$1.6M
- Wajeeha YousafHouston$1.3M
- Laila HassanHouston$870K
- Shervin AssassiHouston$667K
- Jacqueline VoHouston$520K
- Paul PickrellAustin$40.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.